FindTrial
Sign In

Surovatamig

DRUG4 trials

Sponsors

AstraZeneca

Conditions

B-cell Non-Hodgkin LymphomaChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)Rheumatoid ArthritisSystemic Lupus ErythematosusUntreated Follicular Lymphoma

Phase 1

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RecruitingNCT07201558
AstraZenecaRheumatoid Arthritis, Systemic Lupus Erythematosus
Start: 2025-12-02End: 2028-06-27Target: 48Updated: 2026-02-17

Phase 2

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingNCT06526793
AstraZenecaB-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
Start: 2024-11-27End: 2029-06-14Target: 240Updated: 2026-02-25

Phase 3

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingNCT06549595
AstraZenecaUntreated Follicular Lymphoma
Start: 2024-08-07End: 2031-11-26Target: 1018Updated: 2026-03-18
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Not yet recruitingNCT07509151
AstraZenecaChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Start: 2026-04-08End: 2033-08-29Target: 420Updated: 2026-04-03

Related Papers

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma
Blood2025-11-03
Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)
Blood2025-11-03
SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma
Blood2025-11-03